

1. Record Nr.	UNINA9910958947303321
Titolo	Antivirals for pandemic influenza : guidance on developing a distribution and dispensing program // Committee on Implementation of Antiviral Medication Strategies for an Influenza Pandemic, Board on Population Health and Public Health Practice, Institute of Medicine of the National Academies
Pubbl/distr/stampa	Washington, DC, : National Academies Press, c2008
ISBN	9786611767525 9780309185691 0309185696 9781281767523 1281767522 9780309118675 0309118670
Edizione	[1st ed.]
Descrizione fisica	1 online resource (x, 122 pages)
Disciplina	614.518
Soggetti	Antiviral agents - Effectiveness Antiviral agents Epidemics - Prevention Influenza - Prevention Influenza, Human - prevention & control Antiviral Agents - supply & distribution Program Development - methods Antiviral Agents - therapeutic use Disease Outbreaks - prevention & control
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references.
Nota di contenuto	Introduction -- Antiviral effectiveness, safety, and supply -- Ethics, decision making, and communication -- Who should get antivirals and where?
Sommario/riassunto	Planning for an influenza pandemic, whether it occurs in the near or

distant future, will need to take into account many constantly evolving factors. The Institute of Medicine (IOM) Committee on Implementation of Antiviral Medication Strategies for an Influenza Pandemic was asked by the Department of Health and Human Services, (DHHS) to consider best practices and policies for providing antiviral treatment and prophylaxis during a pandemic event. The committee (TM)s report, entitled Antivirals for Pandemic Influenza: Guidance on Developing a Distribution and Dispensing Program, calls for a national and public process of creating an ethical framework for antiviral use within the context of uncertainty and scarcity. It is unclear whether antivirals will work against a pandemic strain as well as they work against seasonal influenza. Also, government stockpiles may not be sufficient for all possible uses in part because antivirals are costly and public health agencies must invest in other important activities, including other medical resources for pandemic influenza. Furthermore, the report identifies the lack of a science-based advisory body to guide decision making during the pandemic, including guidance on all dimensions of antiviral dispensing (for example, prioritization, drug safety, and antiviral resistance). The report also acknowledges the need for diverse methods and sites of dispensing, and discusses their advantages and disadvantages.

---